Difference between revisions of "Vinorelbine (Navelbine)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.pierre-fabre.com/us/file/nvb_prescribing_info_us.pdf Vinorelbine (Navelbine) package insert]</ref><ref>[ht...")
 
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: <ref name="insert">[http://www.pierre-fabre.com/us/file/nvb_prescribing_info_us.pdf Vinorelbine (Navelbine) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/vinorelbine.pdf Vinorelbine (Navelbine) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.  Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.<ref name="insert">[http://www.pierre-fabre.com/us/file/nvb_prescribing_info_us.pdf Vinorelbine (Navelbine) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/vinorelbine.pdf Vinorelbine (Navelbine) package insert (locally hosted backup)]</ref>
<br>Route: TBD
+
<br>Route: IV
<br>Extravasation: TBD
+
<br>Extravasation: [[vesicant]]
  
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>.  
  
 
==Patient drug information==
 
==Patient drug information==
*[http://chemocare.com/bio/vinorelbine.aspVinorelbine (Navelbine) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/vinorelbine.aspVinorelbine (Navelbine) patient drug information (Chemocare)]</ref>
+
*[http://chemocare.com/bio/vinorelbine.asp Vinorelbine (Navelbine) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/vinorelbine.asp Vinorelbine (Navelbine) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/vinorelbine-patient-drug-information Vinorelbine (Navelbine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vinorelbine-patient-drug-information Vinorelbine (Navelbine) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/vinorelbine-patient-drug-information Vinorelbine (Navelbine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vinorelbine-patient-drug-information Vinorelbine (Navelbine) patient drug information (UpToDate)]</ref>
  
 
==References==
 
==References==
 
<references/>
 
<references/>

Revision as of 02:58, 26 February 2012

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase. Vinorelbine may possibly also disrupt: amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent calcium transport ATPase activity; and DNA/RNA and lipid synthesis.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].

Patient drug information

References